# ClearPoint Neuro Inc. (CLPT) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $9.71, market value $311 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). ClearPoint Neuro Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 6.8×**. Each dollar of revenue is priced at 6.8×.
- **Price / book: 11.4×**. The shares trade at 11.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -10.7%** (5-yr avg -6.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 61.4%**. ClearPoint Neuro Inc. keeps 61.4% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -70.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -69.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -91.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -81.3%**. Return on all capital, debt included, is -81.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -37.0%**. Each dollar of assets produces -37.0% of profit.

## Growth
- **Revenue growth (1 yr): 17.8%** (3-yr 21.6%/yr, 5-yr 23.6%/yr). Revenue grew 17.8% over the last year, against 23.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -28.6%**. Earnings per share fell 28.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 1.75**. Debt is 1.75 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. ClearPoint Neuro Inc. holds more cash than debt.
- **Current ratio: 5.91** (quick 5.91). Current assets cover the next year's liabilities 5.91 times.
- **Altman Z-score: 3.29**. A Z-score of 3.29 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. ClearPoint Neuro Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (2 analysts). 2 analysts cover ClearPoint Neuro Inc.; the consensus is strong_buy, with an average price target of $21.50 (+121% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -48.9%** (YTD -29.0%, 3-mo -24.6%). The shares are down 48.9% over twelve months including dividends.
- **From 52-week high: -50.5%** (17.4% above the low). Trading 51% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 1.87** (volatility 87%). Beta of 1.87 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CLPT · Page: https://foliofundamentals.com/stocks/clpt

Not investment advice.